FLT3 and acute myeloid leukemia: Preliminary data from the QuANTUM-First study showed that the upfront addition of quizartinib to intensive chemotherapy in patients with an FLT3-ITD mutant AML resulted in improved OS with placebo (median 31.9 months vs. 15.1 months, p = 0.03) and a lower post-induction FLT3-ITD NGS-MRD level (median VAF 0.01% vs. 0.03%, p = 0.02).